HPV chimaeric particle

Patent metadata

Field	Value
Publication number	US-9771397-B2
Application number	US-201214360524-A
Country	US
Kind code	B2
Filing date	Dec 3, 2012
Priority date	Dec 1, 2011
Publication date	Sep 26, 2017
Grant date	Sep 26, 2017

Abstract

This invention relates to a chimaeric human papillomavirus (HPV) virus like particle (VLP) having a diameter of about 30 nm. The invention further relates to methods of treatment and/or prophylaxis of HPV infection and/or cervical cancer by administration of the chimaeric HPV VLP of the invention to a subject.

First claim

The invention claimed is:

1. A chimaeric human papillomavirus (HPV) virus like particle (VLP) having a diameter of about 30 nm, wherein the chimaeric HPV VLP is produced according to a method comprising:
(i) providing a chimaeric human codon-optimised nucleotide sequence encoding a chimaeric HPV 16 L1/L2 polypeptide, the chimaeric HPV 16 L1/L2 polypeptide comprising an HPV 16 L1 polypeptide having an HPV L2 peptide of between about 13 amino acids to about 26 amino acids inserted from residue 414 of the HPV 16 L1/L2 polypeptide, wherein the amino acids of the inserted HPV L2 peptide replace the amino acids of the HPV 16 L1 polypeptide;
(ii) cloning the chimaeric human codon-optimised nucleotide sequence into an expression vector adapted to express a polypeptide in a plant;
(iii) transforming or infiltrating a plant cell with the expression vector of step (ii);
(iv) expressing the chimaeric HPV 16 L1/L2 polypeptide in the plant cell of step (iii) such that the expressed chimaeric HPV 16 L1/L2 polypeptide assembles into a chimaeric HPV VLP having a diameter of about 30 nm; and
(v) recovering the chimaeric HPV VLP from the plant cell using a high salt extraction buffer having a NaCl concentration of at least 1M.

2. The chimaeric HPV VLP of claim 1 , wherein the inserted HPV L2 peptide is selected from the group consisting of:
(i) a 13 amino acid peptide of SEQ ID NO: 3 encoded by a human codon-optimised nucleotide sequence of SEQ ID NO: 7;
(ii) a 20 amino acid peptide of SEQ ID NO: 5 encoded by a human codon-optimised nucleotide sequence of SEQ ID NO: 9; and
(iii) a 26 amino acid peptide of SEQ ID NO: 4 encoded by a human codon-optimised nucleotide sequence of SEQ ID NO: 8.

3. The chimaeric HPV VLP of claim 1 or 2 , wherein the human codon-optimised nucleotide sequence encoding the chimaeric HPV 16 L1/L2 polypeptide is modified to be nuclear localisation signal deficient.

4. The chimaeric HPV VLP of claim 1 or 2 , wherein the chimaeric HPV 16 L1/L2 polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 22, SEQ ID NO: 23 and SEQ ID NO: 24.

5. The chimaeric HPV VLP of claim 4 wherein the chimaeric HPV 16 L1/L2 polypeptide is encoded by a human codon-optimised nucleotide sequence selected from the group consisting of SEQ ID NO: 26, SEQ ID NO: 27 and SEQ ID NO: 28.

6. The chimaeric HPV VLP of claim 1 or 2 , wherein the chimaeric HPV 16 L1/L2 polypeptide is expressed in and recovered from a plant.

7. The chimaeric HPV VLP of claim 6 , wherein the chimaeric HPV 16 L1/L2 polypeptide is targeted to a chloroplast of the plant.

8. A method of preventing or treating HPV infection in a subject, the method comprising administering a therapeutically effective amount of the chimaeric HPV VLP of claim 1 or 2 to the subject.

9. A method eliciting an immune response against a chimaeric HPV VLP in a subject, the method comprising administering a therapeutically effective amount of the chimaeric HPV VLP of claim 1 or 2 to the subject.

10. The method of claim 9 , wherein the immune response is a neutralising antibody response or a cytotoxic T lymphocyte response.

11. The method of claim 9 , wherein the immune response is a cross-protective immune response to multiple HPV types present in the subject.

12. The method of claim 8 , wherein the subject is human.

13. A pharmaceutical composition comprising the chimaeric HPV VLP of claims 1 or 2 and a pharmaceutically acceptable carrier or adjuvant.

Assignees

• Univ Cape Town

Inventors

• Rybicki Edward Peter
• Hitzeroth Inga Isabel

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P31/12

  Antivirals · CPC title

• A61K2039/5258

  Virus-like particles · CPC title

• C12N7/045

  Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered · CPC title

• C12N15/62 Primary

  DNA sequences coding for fusion proteins · CPC title